The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
It’s absolute nothing. Having a great product is not company changing, we already have one of those.
The only thing company changing is big sales and if we don’t get them soon, I can see GDR needing more funding.
'good things will come to those wait, proven many times'
Certainly in terms of AIM, there are also many cases where holding on to shares causes you to lose more. I don't believe that it will happen here otherwise I wouldn't remain invested.
Leave the confirmation bias at the door when you post, it's not hard to be balanced.
It's not a surprise that they didn't convert the whole lot when you think of it. They know that if they dumped all of their shares all at once that this would lower the price that they would be able to sell at. By converting a smaller amount, they can maximise the average share price that they sell the converted shares at whilst still receiving interest for the remaining loan.
I would have thought an investor of your calibre would know this!
Remember last Thursday when you spewing your usual 'NT to buy' BS? Thought this was going to breakout? I thought this was going to hit 150p into the weekend?
Ultimately it comes down to sales and if we continue to get no sales then that’s really bad news. He doesn’t have to keep updating the market saying ‘no sales yet’, so not all bad news would get an RNS.
Failed approvals is slightly different. We would get an RNS for sure if that happened.
Magzy, one of your first posts compared GDR hitting £3 now to GDR being £3 in 2015. I would suggest understanding the term ‘market cap’ and ‘shares in issue’. If you have already learnt the basics of the markets since this embarrassment then good for you.
A week or so ago you claimed that because we had a spreadex holdings RNS that we would ‘blast off’ because a week after a spreadex holdings RNS in the past, the share price rose. You ignored the fact that there were other RNSs released at that time and also that there have been other spreadex holdings RNSs that have not November the share price.
You have shown yourself to be a complete novice when it comes to investing. Anybody can check you history to verify what I have said above.
He is not free to say he will update the market shortly. Fact. He can say this in an RNS but nowhere else.
He can say that news will be released when there is something to update shareholders with. Which is what he and investor relations actually say.
You make some good points Charlie but then you spoil it by not offering a balanced view.
As I am sure you know, the AIM market is also full of rampers who over inflate the value of companies for their own benefit. You will also know that AIM investors end up losing more than profiting.
As someone who has remained invested since May, I can understand why some people who have been invested for good length of time find it hard to sell. We know that good news here is still realistic and we also know that if good news does come that a substantial rise is also realistic. The idea of missing out on that potential is enough to keep people invested, even if they are unhappy.
I, like you, still believe that good things will come eventually but can easily see it taking another month or so. I am patient though, I intend to see this out.
In regards to DB, I don’t think he has done anything great nor terrible. I think having foresight to enter the covid market is not a great achievement as it would seem to me like a fairly obvious decision to make as a diagnostics company. If anything, the company arrived a month too late to the market. We will never really know whether he could have done more to get things moving faster but I will give him the benefit of the doubt, for now at least.